Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

5-Methoxy 2-aminoindane - Clearmind Medicine

Next Previous
Drug Profile

5-Methoxy 2-aminoindane - Clearmind Medicine

Alternative Names: 5-MeO-AI - Clearmind Medicine; CMND-100; MEAI - Clearmind Medicine

Latest Information Update: 13 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clearmind Medicine
  • Developer Clearmind Medicine; SciSparc
  • Class Amines; Antipsychotics; Drug withdrawal therapies; Ethers; Indans; Obesity therapies
  • Mechanism of Action 5-HT1A serotonin receptor modulators; Serotonin 5-HT2A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Alcoholism
  • Preclinical Cocaine-related disorders; Metabolic syndrome; Obesity

Most Recent Events

  • 05 Aug 2025 Clearmind Medicine receives Institutional Review Board (IRB) approval from Israel for phase I/IIa clinical trial in Alcohol use disorder
  • 30 Jul 2025 Clearmind Medicine files an International patent application for 5-Methoxy 2-aminoindane combination therapy
  • 03 Jul 2025 Clearmind Medicine receives approval from Institutional Review Board (IRB) to initiate the phase I/IIa trial of 5-Methoxy 2-aminoindane in Alcoholism in Israel

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top